



UNITED STATES PATENT AND TRADEMARK OFFICE

JUL 27 2000

Commissioner for Patents
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

David T. Read
Acting Director Regulatory Policy Staff, CDER
Food and Drug Administration
1451 Rockville Pike, HFD-7
Rockville, MD 20852

Re: EVISTA® (raloxifene hydrochloride)
FDA Docket No. 95E-

#17

Dear Mr. Read:

Transmitted herewith is a copy of the application for patent term extension of U.S. Patent No. 4,418,068. The application was filed on January 20, 1998 (duplicate filed May 12, 1999), under 35 U.S.C. § 156.

The patent claims a product that was subject to regulatory review under the Federal Food, Drug and Cosmetic Act. Subject to final review, the subject patent is considered to be eligible for patent term restoration. Thus, a determination by your Office of the applicable regulatory review period is necessary. Accordingly, notice and a copy of the application are provided pursuant to 35 U.S.C. § 156(d)(2)(A).

Telephone inquiries regarding this matter should be directed to the undersigned at (703)306-3159.

Karin Tyson
Senior Legal Advisor
Office of Patent Legal Administration
Office of the Assistant Commissioner for Patent Examination Policy

cc: James J. Sales
ELI LILLY AND COMPANY
PATENT DIVISION/JJS LILLY CORPORATE CENTER
INDIANAOLIS IN 46285

kt